Inhibition of steroid sulphatase activity via the percutaneous route: A new option for breast cancer therapy

Anticancer Research

Volumn 28, Issue 3 A, 2008, Pages 1517-1523

  Purohit, A ^a   Chander, S K ^a   Woo, L W L ^b   Parsons, M F C ^a   Jhalli, R ^a   Potter, B V L ^b   Reed, M J ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b University of Bath   (United Kingdom)

Author keywords

Acne; Androgen; Breast cancer; Hirsutism; Oestrogen; Skin; Steroid sulphatase; Sulphatase inhibitor

Indexed keywords

BN 83495; COUMARIN DERIVATIVE; ESTRADIOL; ESTRONE; ESTRONE SULFATE; PRASTERONE; PRASTERONE SULFATE; STERYL SULFATASE; STX 289; STX 64; TESTOSTERONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIVER; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SKIN;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, TOPICAL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEMALE; HUMANS; LIVER NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLATION; MICE; MICE, NUDE; STERYL-SULFATASE; SULFONIC ACIDS;

EID: 45949094171     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Reed MJ, Hutton JD, Baxendale PM, James VHT, Jacobs HS and Fisher RP: The conversion of androstenedione to oestrone and production of oestrone in women with endometrial cancer. J Steroid Biochem 11: 905-911, 1979.
2. Longcope C, Pratt JH, Schneider SH and Fineberg SE: In vivo studies on the metabolism of estrogens by muscle and adipose tissue in normal males. J Clin Endocrinol Metab 45: 1134-1145, 1977.
3. James VHT, McNeill JM, Lai LC, Newton CJ, Ghilchik MW and Reed MJ: Aromatase activity in normal breast and breast tumor tissue: in vivo and in vitro studies. Steroids 50: 269-279, 1987.
4. Peltoketo H, Isoma V, Maentausta O and Vikko R: Complete amino acid sequence of human placental 17β-hydroxysteroid dehydrogenase deduced from cDNA. FEBs Lett 239: 73-77, 1988.
5. Smith IE and Dowsett M: Aromatase inhibitors in breast cancer. N Engl J Med 348: 2431-2442, 2003.
6. Coombes RC, Hall E, Gibson LJ et al: A randomised trial of exemestane after two to three years of tamoxifen in postmenopausal women with primary breast cancer. N Engl J Med 350: 1081-1082, 2004.
7. Reed MJ, Purohit A, Woo LWL, Newman SP and Potter BVL: Steroid sulphatase: molecular biology, regulation and inhibition. Endocr Rev 26: 171-202, 2005.
8. Poulin R and Labrie F: Stimulation of cell proliferation and estrogenic response by adrenal C19-delta 5 steroids in the ZR-75-1 human breast cancer cell line. Cancer Res 46: 4933-4937, 1986.
9. Stanway SJ, Purohit A, Woo LWL et al: Phase I study of STX64 (667 COUMATE) in breast cancer patients: the first study of a0 steroid sulfatase inhibitor. Clin Cancer Res 12: 1585-1590, 2006.
10. Purohit A, Fusi L, Brosens J, Woo LWL, Potter BVL and Reed MJ: Inhibition of steroid sulphatase activity in endometriotic implants by 667 COUMATE: a potential new therapy. Human Reprod 23: 290-297, 2008
11. Hoffmann R, Rot A, Niiyama N and Billich A: Steroid sulfatase in the human hair follicle concentrates in the dermal papilla. J Invest Dermatol 117: 1342-1348, 2001.
12. Billich A, Meingassner JG, Nussbaumer P, Desrayand S, Lam C, Winishi A and Schreiner E: 6-[2-(Adamantylidene)-hydroxy-benzoxazole]-O-sulfamate, a steroid sulfatase inhibitor for the treatment of androgen and estrogen-dependent diseases. J Steroid Biochem Mol Biol 92: 29-37, 2004.
13. Chen WC, Thiboutot D and Zouboulis CC: Cutaneous androgen metabolism: research and clinical perspectives. J Invest Dermatol 119: 992-1007, 2002.
14. Battaglioli T and Martinelli I: Hormone therapy and thromboembolic disease. Curr Opin Hematol 14: 488-493. 2007.
15. Ho YT, Purohit A, Vicker N, Newman SP, Robinson JJ, Leese MP, Ganeshapillai D, Woo LWL, Potter BVL and Reed MJ: Inhibition of CAII activity by steroidal and non-steroidal sulphamates. Biochem Biophys Res Commun 305: 909-914, 2003.
16. Woo LWL, Purohit A, Malini B, Reed MJ and Potter BVL: Potent active site-directed inhibition of steroid sulfatase by tricyclic coumarin-based sulphamates. Chem Biol 7: 773-791, 2000.
17. Duncan L, Purohit A, Howarth NM, Potter BVL and Reed MJ: Inhibition of estrone sulfatase activity by estrone-3-methylthio-phosphonate - a potential therapeutic agent in breast cancer. Cancer Res 53: 298-303, 1993.
18. Purohit A, Hejaz HAM, Woo LWL, van Strien AE, Potter BVL and Reed MJ: Recent advances in the development of steroid sulphatase inhibitors. J Steroid Biochem Mol Biol 69: 227-238. 1999.
19. Malini B, Purohit A, Ganeshapillai D, Woo LWL, Potter BVL and Reed MJ: Inhibition of steroid sulphatase activity by tricyclic coumarin sulphamates. J Steroid Biochem Mol Biol 75: 253-258, 2000.
20. Ireson CR, Parish D, Woo LWL, Potter BVL, Chander SK and Reed MJ: Development of a sensitive high-performance liquid chromatography method for the detection of 667 COUMATE in vivo. J Steroid Biochem Mol Biol 84: 337-342, 2003.
21. Vicker N, Ho YT, Robinson J, Woo LWL, Purohit A, Reed MJ and Potter BVL: Docking studies of sulphamate inhibitors of estrone sulphatase in human carbonic anhydrase II. Bioorg Med Chem Lett 13: 863-865, 2003.
22. Billich A, Rot A, Lam C, Schmidt JB and Schuster I: Immunohistochemical localization of steroid sulfatase in acne lesions: implications for the contribution of dehydro-epiandrosterone sulfate to the pathogenesis of acne. Horm Res 532: 99 (Abstract 22), 2000.
23. Namazi MR: Steroid sulfatase inhibitors as novel additions to the antipsoriatic armamentarium. Med Sci Monit 11: HY7-9, 2005.
24. Daynes RA, Araneo BA, Dowell TA, Huang K and Dudley D: Regulation of murine lymphokine production in vivo. J Exp Med 171: 979-996, 1990.
25. Rook GAW, Hernandez-Pando R and Lightman S: Hormones, peripherally activated hormones and regulation of Th1/Th2 balance. Immunology Today 15: 301-303, 1994.
26. Reed MJ: The discriminant function test: a marker of Th1/Th2 cytokine secretion and breast tumour oestrogen synthesis. Mol Med Today 1:98-103, 1995.